CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Discussing CAR T as an Early Treatment Option for B-Cell Lymphoma

September 12th 2025

Panelists discuss how community oncologists should introduce CAR T therapy during the first consultation with lymphoma patients to provide reassurance about available treatment options and establish the full treatment pathway.

Second-Line Axi-Cel and Liso-Cel Lead as Standards of Care in LBCL

September 11th 2025

Supriya Gupta, MD, discussed the utility of axi-cel and liso-cel in real-world settings as second-line treatment in large B-cell lymphoma.

Peak CAR T-Cell Expansion Associated With Reduced Relapse Risk Following Brexu-Cel Consolidation in B-ALL

September 4th 2025

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

GD2-Directed CAR T-Cell Therapy Generates Early Antitumor Activity in H3K27M-Mutant Diffuse Midline Glioma

September 3rd 2025

Michelle Monje, MD, PhD, highlights early efficacy data with a GD2-directed CAR T-cell therapy for H3K27M-mutant diffuse midline gliomas.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Experts Expand on the Impact of Removing REMS Requirements for CAR T-Cell Access in Hematologic Malignancies

August 21st 2025

Three experts discuss the implications of the FDA's removal of REMS requirements for CAR T-cell therapy in hematologic malignancies in the following video.

Removal of REMS Requirements Improves Access to CAR T-Cell Therapy Across Hematologic Malignancies

August 18th 2025

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

Real-World Data Highlight Feasibility of CAR T-Cell Therapy in Patients With Aggressive Lymphomas and Active Autoimmune Disease

August 14th 2025

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

CD19 t-haNK Leads to Complete Responses in Waldenstrom Macroglobulinemia

August 13th 2025

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

LV20.19 CAR T-Cell Therapy Yields 100% ORR in R/R Mantle Cell Lymphoma

August 11th 2025

LV20.19 CAR T therapy produced an 88% CR rate and 100% ORR in relapsed/refractory mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 8/3

August 9th 2025

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

FDA Grants RMAT Designation to Novel CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

August 8th 2025

The FDA granted regenerative medicine advanced therapy designation to GLPG5101 for relapsed/refractory mantle cell lymphoma.

Questions Arise As CAR T-Cell Therapy and Bispecific Antibody Use Increase in Relapsed/Refractory Myeloma

August 6th 2025

Prerna Mewawalla, MD, highlights sequencing strategies with CAR T-cell therapy and bispecific antibodies in managing relapsed/refractory multiple myeloma.

FDA Approves Tocilizumab Biosimilar for CAR T-Cell Therapy–Induced CRS

August 6th 2025

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Investigation of SENTI-202 in R/R AML Continues After Confirming RP2D

August 5th 2025

A dose-expansion cohort will further evaluate SENTI-202 in relapsed/refractory acute myeloid leukemia.

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma

August 4th 2025

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.